Major Milestone For SK Biopharm As Anti-Epileptic Gets US Approval
SK Biopharmaceuticals receives US approval for novel anti-epileptic drug, marking a major milestone for the South Korean firm in its goal of becoming a fully integrated global pharma and potentially boosting its huge planned IPO. Through its US subsidiary, the SK Group company will independently market and sell the product in the world’s biggest single market.
You may also be interested in...
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.
The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.
From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.